Literature DB >> 11701257

National survey of West syndrome in Taiwan.

C Young1.   

Abstract

In the fall of 2000, the Taiwan Child Neurology Society performed a retrospective survey of West syndrome that occurred in 1998 and 1999 in Taiwan. Questionnaires were sent to the child neurologists in 15 major teaching hospitals or medical centers throughout Taiwan. There were totally 41 cases in these 2 years. Among these 41 cases, 35 had complete data and were enrolled for analysis. The male to female ratio was 1:1.19. The mean age of onset was 6.0+/-4.9 months old. Twenty nine percent were classified as cryptogenic and 71% were symptomatic. Adrenocorticotropic hormone (ACTH) was given to 40% of these patients. The initial response rate was 78.6% and the recurrence rate was 36.4%. For those patients not receiving ACTH, vigabatrin and valproic acid were two of the most common choices. At the final visit, 37% patients remained seizure-free, 29% were still suffering from the same seizure, and 34% changed to other seizure types. The final developmental status was normal in 14%, mildly retarded in 20%, and moderate to severely retarded in 66% of the patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701257     DOI: 10.1016/s0387-7604(01)00271-6

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  3 in total

1.  Effect of price increase of adrenocorticotropic hormone on treatment practices of infantile spasms.

Authors:  Carter D Wray; Timothy A Benke
Journal:  Pediatr Neurol       Date:  2010-09       Impact factor: 3.372

2.  West syndrome in South Iran: electro-clinical manifestations.

Authors:  Ali Akbar Asadi-Pooya; Mohaddese Sharifzade
Journal:  Iran J Child Neurol       Date:  2013

3.  Latitudinal differences on the global epidemiology of infantile spasms: systematic review and meta-analysis.

Authors:  Jason L Jia; Shiyi Chen; Vishalini Sivarajah; Derek Stephens; Miguel A Cortez
Journal:  Orphanet J Rare Dis       Date:  2018-11-29       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.